FDA Accepts Biologics License Application For Empliciti As Adjunct Treatment for Multiple Myeloma
News
Pharmaceutical giants Bristol-Myers Squibb Company and AbbVie announced the US Food and Drug Administration (FDA) has accepted their Biologics License Application (BLA) for Empliciti (elotuzumab), an investigational Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody, indicated ... Read more